$9.49
0.11% today
NYSE, Jun 06, 10:10 pm CET
ISIN
US91912E1055
Symbol
VALE

Vale S.A. Stock News

Positive
Seeking Alpha
6 days ago
Vale's management provided key updates to analysts, reinforcing my investment thesis with fresh insights from the May 28 meeting. Supply side reforms in China and the potential for higher steel prices could significantly benefit Vale's iron ore business. Mine depletion is a critical, underappreciated factor, potentially offsetting new supply from the Simandou project and supporting iron ore pri...
Negative
Reuters
7 days ago
Brazilian power grid operator ONS told Reuters it denied miner Vale's request to increase power consumption at its northern Onca Puma nickel complex, after missing a deadline to confirm the bid.
Positive
Seeking Alpha
9 days ago
Vale is reinventing itself beyond iron ore, pivoting toward copper and nickel to align with global electrification and energy transition trends. Operational efficiency is improving: C1 iron ore costs dropped 11% YoY, while copper production grows with strong byproduct revenue. Despite weak Q1 results and FCF drop, margins remain solid, and valuation multiples (P/E 5.4x, EV/EBITDA 3.9x) suggest ...
Neutral
Forbes
17 days ago
Vale (NYSE:VALE) stock has not performed particularly well this year, increasing by approximately 10% year to date. In comparison, competitor ArcelorMittal (NYSE:MT) experienced a 36% rise, and United States Steel stock (NYSE:X) saw an increase of 26% during the same timeframe.
Positive
Seeking Alpha
23 days ago
I analyze 50 Bloomberg 'Companies to Watch' for 2025, focusing on the 35 that pay dividends and applying the yield-based dogcatcher strategy. 15 of these dividend payers are 'safer' stocks, with free cash flow yields exceeding dividend yields—five are IDEAL candidates for watch-to-buy. Top ten dividend dogs offer estimated average net gains of 21.33% for the coming year, but investors should be...
Neutral
Business Wire
23 days ago
LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open in the UK. The trial is evaluating AVB-101, an investigational gene therapy, in people with frontotemporal dementia (FTD) with GRN gene mutations...
Positive
Seeking Alpha
about one month ago
In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process involves analyzing financial ratios, competitive advantages, valuations, and diversification across industries and countries to minimize risks and maximize returns. Highlighted top picks for May 2025...
Negative
Seeking Alpha
about one month ago
Vale's net revenue decreased by 4% YoY and 20% QoQ to $8.1 billion due to lower price realization in the ferrous division and seasonal rain effects. Despite this downturn, I foresee improvement as the resolution of the tariff impasse may prompt China to boost infrastructure and civil construction investments. The weak revenue performance is primarily attributed to external factors, suggesting p...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today